2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
(1) To compare the efficacy of two innovative preventative interventions with a control intervention in improving quality of life, cognition, work participation and productivity, brain plasticity and resilience, (2) to gain insight into the…